FI3474846T3 - Muskariinisen asetyylikoliinireseptorin m4 positiiviset allosteeriset modulaattorit - Google Patents
Muskariinisen asetyylikoliinireseptorin m4 positiiviset allosteeriset modulaattorit Download PDFInfo
- Publication number
- FI3474846T3 FI3474846T3 FIEP17816196.4T FI17816196T FI3474846T3 FI 3474846 T3 FI3474846 T3 FI 3474846T3 FI 17816196 T FI17816196 T FI 17816196T FI 3474846 T3 FI3474846 T3 FI 3474846T3
- Authority
- FI
- Finland
- Prior art keywords
- thieno
- dimethylpyrimido
- methyl
- amine
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Liquid Crystal Substances (AREA)
- Control Of El Displays (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353447P | 2016-06-22 | 2016-06-22 | |
| US201662418638P | 2016-11-07 | 2016-11-07 | |
| US201762471281P | 2017-03-14 | 2017-03-14 | |
| PCT/US2017/038711 WO2017223290A1 (en) | 2016-06-22 | 2017-06-22 | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3474846T3 true FI3474846T3 (fi) | 2023-02-16 |
Family
ID=60675830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17816196.4T FI3474846T3 (fi) | 2016-06-22 | 2017-06-22 | Muskariinisen asetyylikoliinireseptorin m4 positiiviset allosteeriset modulaattorit |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10239887B2 (enExample) |
| EP (2) | EP3474846B1 (enExample) |
| JP (1) | JP7038414B2 (enExample) |
| KR (1) | KR102474326B1 (enExample) |
| CN (2) | CN116178391A (enExample) |
| AU (1) | AU2017281228B2 (enExample) |
| BR (1) | BR112018003417B1 (enExample) |
| CL (1) | CL2018003669A1 (enExample) |
| CO (1) | CO2018013600A2 (enExample) |
| CR (1) | CR20180598A (enExample) |
| DK (1) | DK3474846T3 (enExample) |
| DO (1) | DOP2018000263A (enExample) |
| EC (1) | ECSP18094769A (enExample) |
| ES (1) | ES2936827T3 (enExample) |
| FI (1) | FI3474846T3 (enExample) |
| GE (2) | GEP20207167B (enExample) |
| IL (1) | IL263500B (enExample) |
| JO (1) | JOP20180114B1 (enExample) |
| MA (1) | MA45463A (enExample) |
| MX (1) | MX385384B (enExample) |
| NI (1) | NI201800141A (enExample) |
| PE (1) | PE20190446A1 (enExample) |
| PH (1) | PH12018502638B1 (enExample) |
| RU (1) | RU2750935C2 (enExample) |
| SG (1) | SG11201810794VA (enExample) |
| SV (1) | SV2018005800A (enExample) |
| TN (1) | TN2018000416A1 (enExample) |
| UA (1) | UA125874C2 (enExample) |
| WO (1) | WO2017223290A1 (enExample) |
| ZA (1) | ZA201808219B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2789756T3 (es) | 2015-12-23 | 2020-10-26 | Merck Sharp & Dohme | Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4 |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| FI3474846T3 (fi) | 2016-06-22 | 2023-02-16 | Univ Vanderbilt | Muskariinisen asetyylikoliinireseptorin m4 positiiviset allosteeriset modulaattorit |
| EP3534901B1 (en) | 2016-11-07 | 2022-06-22 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| MA47126A (fr) | 2016-11-07 | 2019-10-30 | Univ Vanderbilt | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 |
| CN109863139B (zh) | 2016-11-07 | 2023-02-17 | 范德比尔特大学 | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| US11299481B2 (en) | 2017-10-20 | 2022-04-12 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
| WO2019113174A1 (en) | 2017-12-05 | 2019-06-13 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| CN110950774B (zh) * | 2019-11-04 | 2021-04-13 | 北京大学 | 蛋白质定量标记试剂及其制备方法与应用 |
| WO2021113478A1 (en) | 2019-12-06 | 2021-06-10 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| AR121260A1 (es) * | 2020-02-05 | 2022-05-04 | Neurocrine Biosciences Inc | Antagonistas del receptor muscarínico 4 y métodos de uso |
| CN116669737A (zh) * | 2020-12-22 | 2023-08-29 | 范德堡大学 | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 |
| WO2022226078A1 (en) * | 2021-04-20 | 2022-10-27 | The Regents Of The University Of California | Therapy for alcohol-related liver disease |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2025129082A1 (en) * | 2023-12-14 | 2025-06-19 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594001A (en) | 1993-04-08 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders |
| US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US20020168761A1 (en) * | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP2004511435A (ja) * | 2000-07-27 | 2004-04-15 | ファルマシア・コーポレーション | うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とβ−アドレナリン作動性拮抗薬の併用療法 |
| US7291733B2 (en) * | 2003-10-10 | 2007-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted tricyclic heterocycles and their uses |
| ES2344007T3 (es) * | 2003-10-14 | 2010-08-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibidores proteina quinasa. |
| US20090099165A1 (en) * | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| AR049300A1 (es) | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
| EP1773840B1 (de) | 2004-07-23 | 2010-01-20 | The Medicines Company (Leipzig) GmbH | Substituierte pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung |
| EP1619196A1 (de) | 2004-07-23 | 2006-01-25 | Curacyte Discovery GmbH | Substituierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und Pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur Verwendung als Inhibitoren der PDA-4 und/oder TNF-alpha Freisetzung |
| CA2583550C (en) | 2004-10-25 | 2013-05-14 | Eli Lily And Company | Thienopyridines as allosteric potentiators of the m4 muscarinic receptor |
| ES2259892B1 (es) | 2004-11-30 | 2007-11-01 | Laboratorios Almirall S.A. | Nuevos derivados de piridotienopirimidina. |
| ES2259891B1 (es) | 2004-11-30 | 2007-11-01 | Laboratorios Almirall S.A. | Nuevos derivados de piridotienopirimidina. |
| WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| AR059901A1 (es) | 2006-03-20 | 2008-05-07 | Bayer Pharmaceuticals Corp | Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares. |
| US20080021063A1 (en) * | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
| US7547781B2 (en) * | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| JP2010514810A (ja) * | 2006-12-29 | 2010-05-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌインヒビターとして有用な置換トリアゾール |
| JP5389013B2 (ja) * | 2007-04-20 | 2014-01-15 | グラクソ グループ リミテッド | 抗菌剤としての三環式含窒素化合物 |
| US20090105240A1 (en) | 2007-10-17 | 2009-04-23 | Tomas Mustelin | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
| US20100009934A1 (en) * | 2008-06-09 | 2010-01-14 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| JP5746172B2 (ja) | 2009-08-20 | 2015-07-08 | カルス セラピューティクス リミテッド | ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物 |
| US20110178107A1 (en) | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| RU2451686C1 (ru) * | 2010-12-27 | 2012-05-27 | Александр Васильевич Иващенко | ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| WO2012131297A1 (en) | 2011-03-28 | 2012-10-04 | Jonathan Bayldon Baell | Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use |
| US9056876B2 (en) | 2011-09-16 | 2015-06-16 | Vanderbilt University | Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| JP6473330B2 (ja) | 2011-12-21 | 2019-02-20 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | ＲａｌＧＴＰアーゼを標的とする抗がん化合物及びその使用方法 |
| US8697888B2 (en) * | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
| ES2656972T3 (es) | 2012-02-23 | 2018-03-01 | Vanderbilt University | Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4 |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| US9056875B2 (en) | 2012-08-31 | 2015-06-16 | Vanderbilt University | Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| WO2015027214A1 (en) * | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| US20160200733A1 (en) | 2013-08-23 | 2016-07-14 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| WO2015200619A1 (en) * | 2014-06-26 | 2015-12-30 | Rodin Therapeutics, Inc. | Inhibitors of histone deacetylase |
| FI3474846T3 (fi) | 2016-06-22 | 2023-02-16 | Univ Vanderbilt | Muskariinisen asetyylikoliinireseptorin m4 positiiviset allosteeriset modulaattorit |
| CN109863139B (zh) * | 2016-11-07 | 2023-02-17 | 范德比尔特大学 | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 |
| EP3534901B1 (en) * | 2016-11-07 | 2022-06-22 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| MA47126A (fr) | 2016-11-07 | 2019-10-30 | Univ Vanderbilt | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 |
| WO2019113174A1 (en) * | 2017-12-05 | 2019-06-13 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
-
2017
- 2017-06-22 FI FIEP17816196.4T patent/FI3474846T3/fi active
- 2017-06-22 MA MA045463A patent/MA45463A/fr unknown
- 2017-06-22 TN TNP/2018/000416A patent/TN2018000416A1/en unknown
- 2017-06-22 JO JOP/2018/0114A patent/JOP20180114B1/ar active
- 2017-06-22 RU RU2018142987A patent/RU2750935C2/ru active
- 2017-06-22 UA UAA201812497A patent/UA125874C2/uk unknown
- 2017-06-22 CN CN202310019545.6A patent/CN116178391A/zh active Pending
- 2017-06-22 KR KR1020187036672A patent/KR102474326B1/ko active Active
- 2017-06-22 AU AU2017281228A patent/AU2017281228B2/en active Active
- 2017-06-22 DK DK17816196.4T patent/DK3474846T3/da active
- 2017-06-22 BR BR112018003417-7A patent/BR112018003417B1/pt active IP Right Grant
- 2017-06-22 GE GEAP201714954A patent/GEP20207167B/en unknown
- 2017-06-22 ES ES17816196T patent/ES2936827T3/es active Active
- 2017-06-22 CN CN201780036134.0A patent/CN109310668B/zh active Active
- 2017-06-22 PE PE2018003237A patent/PE20190446A1/es unknown
- 2017-06-22 CR CR20180598A patent/CR20180598A/es unknown
- 2017-06-22 PH PH1/2018/502638A patent/PH12018502638B1/en unknown
- 2017-06-22 JP JP2018566971A patent/JP7038414B2/ja active Active
- 2017-06-22 EP EP17816196.4A patent/EP3474846B1/en active Active
- 2017-06-22 US US15/630,200 patent/US10239887B2/en active Active
- 2017-06-22 MX MX2018015878A patent/MX385384B/es unknown
- 2017-06-22 WO PCT/US2017/038711 patent/WO2017223290A1/en not_active Ceased
- 2017-06-22 SG SG11201810794VA patent/SG11201810794VA/en unknown
- 2017-06-22 EP EP22202461.4A patent/EP4186910A1/en not_active Withdrawn
- 2017-06-22 GE GEAP202014954A patent/GEAP202014954A/en unknown
-
2018
- 2018-12-03 DO DO2018000263A patent/DOP2018000263A/es unknown
- 2018-12-04 IL IL263500A patent/IL263500B/en unknown
- 2018-12-05 ZA ZA2018/08219A patent/ZA201808219B/en unknown
- 2018-12-12 SV SV2018005800A patent/SV2018005800A/es unknown
- 2018-12-14 CO CONC2018/0013600A patent/CO2018013600A2/es unknown
- 2018-12-18 CL CL2018003669A patent/CL2018003669A1/es unknown
- 2018-12-20 EC ECSENADI201894769A patent/ECSP18094769A/es unknown
- 2018-12-21 NI NI201800141A patent/NI201800141A/es unknown
-
2019
- 2019-01-29 US US16/261,108 patent/US11142532B2/en active Active
-
2021
- 2021-09-08 US US17/469,178 patent/US20230014109A1/en not_active Abandoned
-
2023
- 2023-06-29 US US18/344,555 patent/US20230348490A1/en not_active Abandoned
-
2024
- 2024-10-01 US US18/903,075 patent/US20250026764A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3474846T3 (fi) | Muskariinisen asetyylikoliinireseptorin m4 positiiviset allosteeriset modulaattorit | |
| MA55037A (fr) | Variants d'arn polymérase pour le coiffage co-transcriptionnel | |
| IL271547A (en) | T7 rna polymerase variants | |
| IL271553A (en) | T7 rna polymerase variants | |
| PT3433232T (pt) | Novo sal de adição de ácido de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina | |
| DK3464265T3 (da) | Polymorpher af n-[(3-fluor-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazol-4-carboxamid som kallikrein-inhibitorer | |
| BRPI0920598A2 (pt) | formas sólidas de n-(4(7-azabiciclo[2.2.1]heptan-7-il)-2-(triflúor-metil)fenil)-4-oxo-5-(triflúor-metil)-1,4-di-hidroquinolina-3-carboxamida | |
| IL254132B (en) | A solid preparation of N-(4-(1(2,6-difluorobenzyl)-5-))dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxy-1,2,3 4-tetrahydrothiano[2,3-d]pyrimidine-6-yl)phenyl)-n-methoxyurea or its salt | |
| EP3457456A4 (en) | COMPOSITION FOR FUNCTIONAL LAYER OF A WATER-FREE SECONDARY CELL, FUNCTIONAL LAYER FOR WATER-FREE SECONDARY CELL AND WATER-FREE SECONDARY CELL | |
| EA202091120A3 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| FI3746437T3 (fi) | Proteiinikinaasi mkk4:n estäjiä maksan regeneraation edistämiseen tai maksasolujen kuolemisen vähentämiseen tai ehkäisyyn | |
| DK2598501T3 (da) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamidmesylat-monohydrat | |
| EP2903971A4 (en) | SUBSTITUTED N- (3- (PYRIMIDIN-4-YL-) PHENYL-) ACRYLAMIDE ANALOGUE AS TYROSINE RECEPTOR KINASE-BTK INHIBITORS | |
| EP2903972A4 (en) | SUBSTITUTED N- (3- (PYRIMIDIN-4-YL-) PHENYL-) ACRYLAMIDE ANALOGUE AS TYROSINE RECEPTOR KINASE-BTK INHIBITORS | |
| DK3418275T3 (da) | Hidtil ukendt 2,3,5-substitueret thiophenforbindelse som proteinkinasehæmmer | |
| MA53479A (fr) | Composés hétérocycliques en tant q'inibiteurs de vanin | |
| IL260403B (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| CO2018006834A2 (es) | Composición farmacéutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida | |
| EP4163340C0 (en) | AQUEOUS INK COMPOSITION FOR INKJET | |
| EP2752471A4 (en) | OILED INK COMPOSITION FOR A BALL PEN | |
| EP3330330A4 (en) | NON-WATER INK JET INK COMPOSITION | |
| EP3374444A4 (en) | INK COMPOSITIONS FOR INK INJECTION | |
| EP3543287A4 (en) | COMPOSITION FOR 3D PRINTING | |
| EP3553140A4 (en) | COMPOSITION OF NON-AQUEOUS INK FOR INKJET | |
| EP3480264A4 (en) | WATER-FREE INK-JET MAGNETIC INK COMPOSITION |